Monthly Archives: February 2010
Licensing deals sharply up
BioPharm Insight in its annual Biotechnology and Pharmaceutical Licensing Agreement and M&A Report for 2009 points to a strong rebound in the value of licensing activity in the last quarter of 2009. The quarter saw 139 agreements valued at $17.40 billion, an … Continue reading
Filed under licensing
Anadys shares fall on trial results
Shares in Anadys Pharmaceuticals fell 20% on news that a new batch of Phase II data for, ANA598, their experimental hepatitis C drug worked only slightly better than a placebo. The company had raised $17.5 million from shareholders in June … Continue reading
Filed under Research
Is out-licensing the ‘in thing’ for big pharma?
In Vivo takes an in depth look at out-licensing trends among the big biopharmaceutical companies.
Filed under licensing
Transgene close to selling rights on TG4010?
Bloomberg is reporting that Transgene is close to selling rights on TG4010 with Pfizer, Roche, Novartis and Sanofi-Aventis cited as potential partners. According to the wire service, the chances that Transgene will attract a drugmaker rose in December when US regulators … Continue reading
Filed under alliances
Evotec extends research agreement with Cubist Pharmaceuticals
Evotec has announced that it has extended its research agreement with Cubist Pharmaceuticals to the end of 2010. Under the contract extension, Evotec will provide additional fragment-based drug discovery expertise including fragment screening, structural biology and protein crystallography, to discover … Continue reading
Filed under alliances
Regulus Therapeutics partners with GlaxoSmithKline
Regulus Therapeutics has announced the establishment of a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection as the lead indication. Under the terms of the new collaboration, Regulus … Continue reading
Filed under alliances
HemCon and ProMetic collaboration progresses to the next stage
ProMetic Life Sciences has announced today that it has successfully completed the first phase of work with HemCon Medical Technologies on the development of a single-use antibody capture device for the removal of isoagglutinin antibodies from human plasma. The exclusive … Continue reading
Filed under alliances
Transgenomic licenses technology from IntegraGen
Transgenomic has announced that it has licensed on an exclusive US basis intellectual property from IntegraGen that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings … Continue reading
Filed under alliances
Pfizer, Lilly and Merck partner for cancer research
Eli Lilly and Company, Merck, and Pfizer have announced the formation of the Asian Cancer Research Group, an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. The goal … Continue reading
Filed under alliances
CellCentric licenses epigenetic discovery programme to Takeda
CellCentric has out-licensed the development and commercialisation of a programme focused on cancer. Under the terms of the new agreement, CellCentric will receive an upfront payment and pre-clinical and clinical milestones, plus royalties from Takeda. According to the companies the overall deal … Continue reading
Filed under alliances
